



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/216164/>

Version: Supplemental Material

---

**Article:**

Mukherjee, S., Qi, C., Shaw, R. et al. (2024) Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. *European Journal of Cancer*, 209. 114236. ISSN: 0959-8049

<https://doi.org/10.1016/j.ejca.2024.114236>

---

© 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. This is an author produced version of an article published in *European Journal of Cancer* made available under the CC-BY-NC-ND 4.0 license (<http://creativecommons.org/licenses/by-nc-nd/4.0>) in accordance with the publisher's self-archiving policy.


**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.


**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.


**FIGURES**




**Figure 1: CONSORT flow diagram of stage 2 of the SCALOP-2 trial.**



**Figure 2: Kaplan Meier estimates for stage 2 patients receiving chemoradiotherapy of (A) overall survival by standard versus high dose radiation and (B) progression free survival by nelfinavir usage.**



**Figure 3: Mean EORTC-PAN26 score prior to, immediately, 6-, 18- and 28- weeks following standard (50.4Gy in 28 fractions) and high (60Gy in 30 fractions) dose chemoradiotherapy. Error bars indicate the 95% confidence interval.**



**Figure 4: Mean EORTC-PAN26 score prior to, to immediately, 6-, 18- and 28- weeks following chemoradiotherapy with and without concurrent nelfinavir.** Error bars indicate the 95% confidence interval